Infant Mortality at 12 months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 12 months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
HIV Transmission or Death at 12 Months · HIV‐infected pregnant women
It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes HIV Transmission or Death at 12 Months compared with other Short Course Regimen (very low certainty).
1 finding from 1 review
Infant Mortality at 1 Month · HIV‐infected pregnant women
It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes infant Mortality at 1 Month compared with other Short Course Regimen (very low certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events Requiring Treatment Modification · HIV‐infected pregnant women
It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes maternal Grade 3/4 Severe Adverse Events Requiring Treatment… compared with other Short Course Regimen (very low certainty).
1 finding from 1 review
Low birthweight · HIV‐infected pregnant women
It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes infant Low Birth Weight compared with other Short Course Regimen (very low certainty).
1 finding from 1 review
Stillbirth · HIV‐infected pregnant women
It is very uncertain whether tonwe‐Gold continued: AZT/3TC/NVP changes stillbirths compared with other Short Course Regimen (very low certainty).
1 finding from 1 review
Maternal Mortality at Delivery · HIV‐infected pregnant women
1 finding from 1 review
Mother to Child Transmission at 1 Month · HIV‐infected pregnant women
It is very uncertain whether tonwe‐Gold continued: AZT/3TC/NVP changes mother to Child Transmission of HIV at 1 Month compared with other Short Course Regimen (very low certainty).
1 finding from 1 review
Mother to Child Transmission at 12 Months · HIV‐infected pregnant women
It is very uncertain whether tonwe‐Gold continued: AZT/3TC/NVP changes mother to Child Transmission of HIV at 12 Months compared with other Short Course Regimen (very low certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes maternal Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Infant Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Prematurity · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes prematurity compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).
1 finding from 1 review
Low birthweight · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in low Birth Weight compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Stillbirth · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3
Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in stillbirths compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).
1 finding from 1 review
Intervention not reported
Treatment failure at 1 month or less · patients with acute otitis media
The intervention led to higher treatment failure at 1 month or less; GRADE not reported.
1 finding from 1 review
Intervention not reported
Treatment failure at 8 to 19 days · patients with acute otitis media
The intervention led to higher treatment failure at 8 to 19 days; GRADE not reported.
1 finding from 1 review
Intervention not reported
Treatment failure at 20 to 30 days · patients with acute otitis media
The intervention showed no clear difference in treatment failure at 20 to 30 days; GRADE not reported.
1 finding from 1 review
Intervention not reported
Treatment failure at 8 to 19 days · patients with acute otitis media
The intervention led to higher treatment failure at 8 to 19 days; GRADE not reported.
1 finding from 1 review
Intervention not reported
Treatment failure at 20 to 30 days · patients with acute otitis media
The intervention showed no clear difference in treatment failure at 20 to 30 days; GRADE not reported.
1 finding from 1 review
Intervention not reported
Treatment failure at 3 months or less · patients with acute otitis media
The intervention showed no clear difference in treatment failure at 3 months or less; GRADE not reported.
1 finding from 1 review